93 related articles for article (PubMed ID: 20484184)
1. Letter by George regarding article, "Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled cross-over preliminary study".
George J
Circ Heart Fail; 2010 May; 3(3):e10; author reply e14. PubMed ID: 20484184
[No Abstract] [Full Text] [Related]
2. Uric acid-lowering treatment with benzbromarone in patients with heart failure: a double-blind placebo-controlled crossover preliminary study.
Ogino K; Kato M; Furuse Y; Kinugasa Y; Ishida K; Osaki S; Kinugawa T; Igawa O; Hisatome I; Shigemasa C; Anker SD; Doehner W
Circ Heart Fail; 2010 Jan; 3(1):73-81. PubMed ID: 19933411
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of benzbromarone in hyperuricemic patients associated with chronic kidney disease.
Fujimori S; Ooyama K; Ooyama H; Moromizato H
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1035-8. PubMed ID: 22132953
[TBL] [Abstract][Full Text] [Related]
4. Stopping progression in familial juvenile hyperuricemic nephropathy with benzbromarone?
Lhotta K
Kidney Int; 2003 Nov; 64(5):1920-1. PubMed ID: 14531831
[No Abstract] [Full Text] [Related]
5. Safety and Efficacy of Benzbromarone and Febuxostat in Hyperuricemia Patients with Chronic Kidney Disease: A Prospective Pilot Study.
Yu H; Liu X; Song Y; Cheng J; Bao H; Qin L; Zhou X; Wang L; Peng A
Clin Exp Nephrol; 2018 Dec; 22(6):1324-1330. PubMed ID: 29761242
[TBL] [Abstract][Full Text] [Related]
6. Clinical efficacy and safety of benzbromarone in elderly hypertensive patients with hyperuricemia.
Gao H
Pak J Pharm Sci; 2019 Jul; 32(4(Supplementary)):1869-1871. PubMed ID: 31680085
[TBL] [Abstract][Full Text] [Related]
7. Is hyperuricemia a risk factor for arteriosclerosis? Uric acid and arteriosclerosis in apolipoprotein e-deficient mice.
Wakuda H; Uchida S; Ikeda M; Tabuchi M; Akahoshi Y; Shinozuka K; Yamada S
Biol Pharm Bull; 2014; 37(12):1866-71. PubMed ID: 25451835
[TBL] [Abstract][Full Text] [Related]
8. Effective uric acid-lowering treatment for hypertensive patients with hyperuricemia.
Ohta Y; Ishizuka A; Arima H; Hayashi S; Iwashima Y; Kishida M; Yoshihara F; Nakamura S; Kawano Y
Hypertens Res; 2017 Mar; 40(3):259-263. PubMed ID: 27760998
[TBL] [Abstract][Full Text] [Related]
9. Clinical trials of uric acid lowering for coronary heart disease risk reduction.
Simon JA
Am J Med; 2006 Apr; 119(4):e5; author reply e7. PubMed ID: 16564763
[No Abstract] [Full Text] [Related]
10. Clinical images: Divergent patterns of joint remodeling following effective urate-lowering therapy in tophaceous gout.
Dalbeth N; Doyle A; McQueen FM
Arthritis Rheum; 2011 Jan; 63(1):266. PubMed ID: 20722028
[No Abstract] [Full Text] [Related]
11. Efficacy of benzbromarone compared to allopurinol in lowering serum uric acid level in hyperuricemic patients.
Hanvivadhanakul P; Akkasilpa S; Deesomchok U
J Med Assoc Thai; 2002 Jun; 85 Suppl 1():S40-7. PubMed ID: 12188443
[TBL] [Abstract][Full Text] [Related]
12. Relationship between serum allantoin and urate in healthy subjects and effects of benzbromarone in gout patients.
Kurajoh M; Koyama H; Shoji T; Sumida C; Yamamoto A; Tsutsumi Z; Moriwaki Y; Yamamoto T; Koga M
Int J Clin Pharmacol Ther; 2012 Apr; 50(4):265-71. PubMed ID: 22456297
[TBL] [Abstract][Full Text] [Related]
13. Uric acid: role in cardiovascular disease and effects of losartan.
Alderman M; Aiyer KJ
Curr Med Res Opin; 2004 Mar; 20(3):369-79. PubMed ID: 15025846
[TBL] [Abstract][Full Text] [Related]
14. [Impact of serum uric acid level on the cardiovascular system as a risk factor].
Hisatome I
Nihon Yakurigaku Zasshi; 2010 Dec; 136(6):325-9. PubMed ID: 21139282
[No Abstract] [Full Text] [Related]
15. Uric acid-lowering therapy with benzbromarone in hypertension with asymptomatic hyperuricemia: a randomized study focusing left ventricular diastolic function.
Ke J; Pan J; Lin H; Han Z; Gu J
Curr Med Res Opin; 2023 Jul; 39(7):947-953. PubMed ID: 37300510
[TBL] [Abstract][Full Text] [Related]
16. [Isolated or combined drug therapy of hyperuricemia?].
Mertz DP
Dtsch Med Wochenschr; 1977 Jul; 102(30):1096-7. PubMed ID: 891391
[No Abstract] [Full Text] [Related]
17. Design, synthesis, and biological studies of dual URAT1 inhibitor and FXR agonist based on benzbromarone.
Huang W; Jiao S; Chen S; Chen Y; Yang Z; Wang W; Cao Z; Li Z; Zhang L
Bioorg Med Chem; 2022 Dec; 75():117073. PubMed ID: 36347120
[TBL] [Abstract][Full Text] [Related]
18. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
19. [The uric acid-lowering action of benzbromarone effervescent granules and allopurinol. Comparative studies (author's transl)].
Mertz DP
MMW Munch Med Wochenschr; 1978 Oct; 120(42):1387-90. PubMed ID: 101792
[TBL] [Abstract][Full Text] [Related]
20. Benzbromarone as a possible cause of acute kidney injury in patients with urolithiasis: Two case reports.
Ye X; Wu J; Tang K; Li W; Xiong C; Zhuo L
Medicine (Baltimore); 2019 Apr; 98(15):e15214. PubMed ID: 30985721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
